{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T19:24:18Z","timestamp":1750706658303},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T00:00:00Z","timestamp":1407283200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T00:00:00Z","timestamp":1407283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s12013-014-0162-7","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T15:19:24Z","timestamp":1408634364000},"page":"57-62","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy of Adenosine A2A Receptor Antagonist Istradefylline as Augmentation for Parkinson\u2019s Disease: A Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1007","volume":"71","author":[{"given":"Yingqun","family":"Tao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guobiao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,6]]},"reference":[{"key":"162_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2003.tb07458.x","volume":"991","author":"S Fahn","year":"2003","unstructured":"Fahn, S. (2003). Description of Parkinson\u2019s disease as a clinical syndrome. Annals of the New York Academy of Sciences,\n                  991, 1\u201314.","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"162_CR2","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S1471-4914(03)00020-0","volume":"9","author":"A Barzilai","year":"2003","unstructured":"Barzilai, A., & Melamed, E. (2003). Molecular mechanisms of selective dopaminergic neuronal death in Parkinson\u2019s disease. Trends in Molecular Medicine,\n                  9(3), 126\u2013132.","journal-title":"Trends in Molecular Medicine"},{"issue":"6","key":"162_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"W Dauer","year":"2003","unstructured":"Dauer, W., & Przedborski, S. (2003). Parkinson\u2019s disease: mechanisms and models. Neuron,\n                  39(6), 889\u2013909.","journal-title":"Neuron"},{"issue":"5","key":"162_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","volume":"68","author":"ER Dorsey","year":"2007","unstructured":"Dorsey, E. R., et al. (2007). Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology,\n                  68(5), 384\u2013386.","journal-title":"Neurology"},{"issue":"Suppl 1","key":"162_CR5","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00019052-200312001-00004","volume":"16","author":"U Bonuccelli","year":"2003","unstructured":"Bonuccelli, U. (2003). Comparing dopamine agonists in Parkinson\u2019s disease. Current Opinion in Neurology,\n                  16(Suppl 1), S13\u2013S19.","journal-title":"Current Opinion in Neurology"},{"issue":"Suppl 1","key":"162_CR6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00019052-200312001-00002","volume":"16","author":"P Jenner","year":"2003","unstructured":"Jenner, P. (2003). Dopamine agonists, receptor selectivity and dyskinesia induction in Parkinson\u2019s disease. Current Opinion in Neurology,\n                  16(Suppl 1), S3\u2013S7.","journal-title":"Current Opinion in Neurology"},{"issue":"4","key":"162_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11302-008-9100-8","volume":"4","author":"M Cieslak","year":"2008","unstructured":"Cieslak, M., Komoszynski, M., & Wojtczak, A. (2008). Adenosine A(2A) receptors in Parkinson\u2019s disease treatment. Purinergic Signal,\n                  4(4), 305\u2013312.","journal-title":"Purinergic Signal"},{"issue":"11","key":"162_CR8","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1017\/S0033291712002802","volume":"43","author":"MT Berlim","year":"2013","unstructured":"Berlim, M. T., Van den Eynde, F., & Daskalakis, Z. J. (2013). A systematic review and meta-analysis on the efficacy and acceptability of bilateral repetitive transcranial magnetic stimulation (rTMS) for treating major depression. Psychological Medicine,\n                  43(11), 2245\u20132254.","journal-title":"Psychological Medicine"},{"issue":"3","key":"162_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.psychres.2013.09.007","volume":"210","author":"J Chen","year":"2013","unstructured":"Chen, J., et al. (2013). Left versus right repetitive transcranial magnetic stimulation in treating major depression: A meta-analysis of randomised controlled trials. Psychiatry Research,\n                  210(3), 1260\u20131264.","journal-title":"Psychiatry Research"},{"issue":"1","key":"162_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s002130051146","volume":"147","author":"S Shiozaki","year":"1999","unstructured":"Shiozaki, S., et al. (1999). Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology (Berl),\n                  147(1), 90\u201395.","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"162_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","volume":"12","author":"GK Wenning","year":"2013","unstructured":"Wenning, G. K., et al. (2013). The natural history of multiple system atrophy: A prospective European cohort study. Lancet Neurology,\n                  12(3), 264\u2013274.","journal-title":"Lancet Neurology"},{"issue":"15","key":"162_CR12","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1002\/mds.22095","volume":"23","author":"RA Hauser","year":"2008","unstructured":"Hauser, R. A., et al. (2008). Study of istradefylline in patients with Parkinson\u2019s disease on levodopa with motor fluctuations. Movement Disorders,\n                  23(15), 2177\u20132185.","journal-title":"Movement Disorders"},{"issue":"3","key":"162_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ana.21315","volume":"63","author":"PA LeWitt","year":"2008","unstructured":"LeWitt, P. A., et al. (2008). Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces \u201coff\u201d time in Parkinson\u2019s disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Annals of Neurology,\n                  63(3), 295\u2013302.","journal-title":"Annals of Neurology"},{"issue":"23","key":"162_CR14","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1212\/01.wnl.0000313834.22171.17","volume":"70","author":"M Stacy","year":"2008","unstructured":"Stacy, M., et al. (2008). A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology,\n                  70(23), 2233\u20132240.","journal-title":"Neurology"},{"issue":"8","key":"162_CR15","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40265-013-0066-7","volume":"73","author":"R Dungo","year":"2013","unstructured":"Dungo, R., & Deeks, E. D. (2013). Istradefylline: First global approval. Drugs,\n                  73(8), 875\u2013882.","journal-title":"Drugs"},{"issue":"6","key":"162_CR16","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1212\/WNL.42.6.1142","volume":"42","author":"AJ Hughes","year":"1992","unstructured":"Hughes, A. J., et al. (1992). What features improve the accuracy of clinical diagnosis in Parkinson\u2019s disease: a clinicopathologic study. Neurology,\n                  42(6), 1142\u20131146.","journal-title":"Neurology"},{"issue":"8","key":"162_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1056\/NEJM198702193160806","volume":"316","author":"HS Sacks","year":"1987","unstructured":"Sacks, H. S., et al. (1987). Meta-analyses of randomized controlled trials. New England Journal of Medicine,\n                  316(8), 450\u2013455.","journal-title":"New England Journal of Medicine"},{"key":"162_CR18","doi-asserted-by":"publisher","first-page":"d549","DOI":"10.1136\/bmj.d549","volume":"342","author":"RD Riley","year":"2011","unstructured":"Riley, R. D., Higgins, J. P., & Deeks, J. J. (2011). Interpretation of random effects meta-analyses. BMJ,\n                  342, d549.","journal-title":"BMJ"},{"issue":"7414","key":"162_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins, J. P., et al. (2003). Measuring inconsistency in meta-analyses. BMJ,\n                  327(7414), 557\u2013560.","journal-title":"BMJ"},{"issue":"2","key":"162_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.parkreldis.2011.09.023","volume":"18","author":"E Pourcher","year":"2012","unstructured":"Pourcher, E., et al. (2012). Istradefylline for Parkinson\u2019s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism and Related Disorders,\n                  18(2), 178\u2013184.","journal-title":"Parkinsonism and Related Disorders"},{"issue":"8","key":"162_CR21","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.25418","volume":"28","author":"Y Mizuno","year":"2013","unstructured":"Mizuno, Y., Kondo, T., & G. Japanese Istradefylline Study. (2013). Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson\u2019s disease. Movement Disorders,\n                  28(8), 1138\u20131141.","journal-title":"Movement Disorders"},{"issue":"10","key":"162_CR22","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1002\/mds.23107","volume":"25","author":"Y Mizuno","year":"2010","unstructured":"Mizuno, Y., et al. (2010). Clinical efficacy of istradefylline (KW-6002) in Parkinson\u2019s disease: A randomized, controlled study. Movement Disorders,\n                  25(10), 1437\u20131443.","journal-title":"Movement Disorders"},{"issue":"5","key":"162_CR23","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/mds.10226","volume":"17","author":"RA Hauser","year":"2002","unstructured":"Hauser, R. A., & Holford, N. H. (2002). Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson\u2019s disease. Movement Disorders,\n                  17(5), 961\u2013968.","journal-title":"Movement Disorders"},{"issue":"2","key":"162_CR24","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/exnr.2000.7350","volume":"162","author":"T Kanda","year":"2000","unstructured":"Kanda, T., et al. (2000). Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Experimental Neurology,\n                  162(2), 321\u2013327.","journal-title":"Experimental Neurology"},{"issue":"8","key":"162_CR25","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1212\/WNL.52.8.1673","volume":"52","author":"R Grondin","year":"1999","unstructured":"Grondin, R., et al. (1999). Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology,\n                  52(8), 1673\u20131677.","journal-title":"Neurology"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-014-0162-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12013-014-0162-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-014-0162-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-014-0162-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T18:11:31Z","timestamp":1602267091000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12013-014-0162-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,6]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["162"],"URL":"https:\/\/doi.org\/10.1007\/s12013-014-0162-7","relation":{},"ISSN":["1085-9195","1559-0283"],"issn-type":[{"value":"1085-9195","type":"print"},{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,6]]},"assertion":[{"value":"6 August 2014","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}